Immunomodulatory Effect of Gut Microbiota-Derived Bioactive Peptides on Human Immune System from Healthy Controls and Patients with Inflammatory Bowel Disease
Authors:
- Samuel Fernández-ToméSFSamuel Fernández-Tomé
- Alicia C. MarinAMAlicia C. Marin
- Lorena Ortega MorenoLMLorena Ortega Moreno
- Montserrat Baldan-MartinMBMontserrat Baldan-Martin
- Irene Mora-GutiérrezIMIrene Mora-Gutiérrez
- Aitor Lanas-GimenoALAitor Lanas-Gimeno
- José Andrés Moreno-MonteagudoJMJosé Andrés Moreno-Monteagudo
- Cecilio SantanderCSCecilio Santander
- Borja SánchezBSBorja Sánchez
- María ChaparroMCMaría Chaparro
- Javier P. GisbertJGJavier P. Gisbert
- David BernardoDBDavid Bernardo
Open Access
Abstract
Bioactive peptides secreted by probiotic Bifidobacterium longum (peptide B7) and opportunistic pathogen Bacteroides fragilis (peptide B12) modulate the intestinal cytokine milieu in health. Here, we characterized their capacity to modulate both the mucosal cytokine production and the phenotype of circulating antigen presenting cells (APCs) in active inflammatory bowel disease (IBD). The IBD mucosa produced higher levels of pro-inflammatory cytokines referred to healthy controls (HCs). Peptides B7 and B12, however, did not ameliorate the mucosal cytokine milieu in IBD. Human circulating APCs (B-cells, monocytes, plasmacytoid dendritic cells (pDCs), and conventional dendritic cells (cDCs)) were characterized by flow cytometry in presence/absence of the peptides. Circulating B-cells, monocytes, and cDCs from IBD patients were more activated than those from HCs. Peptide B7, but not B12, decreased CCR2 expression on all APC subsets from HC, but not IBD patients. Moreover, both peptides tend to further increase their pro-inflammatory profile in IBD. In summary, IBD patients display mucosal and circulating APC pro-inflammatory properties. Peptide B7 immunomodulatory capacity elicited over circulating APCs from HC, but not IBD patients, suggests the presence of disrupted modulatory mechanisms for this peptide in IBD. Future studies should address the effect of bacteria-derived immunomodulatory peptides in non-inflamed (quiescent) IBD patients.Keywords
Funding Information
- Spanish Ministry of Economy (SAF2014-56642-JIN, RYC-2017-21606)
- Spanish Ministry of Health (PIE13/00041)
- Grupo Español de Trabajo en Enfermedad Crohn y Colitis Ulcerosa (GETECCU)
- Comunidad de Madrid (Consejería de Educación, Juventud y Deporte, Programa de Garantía Juvenil 2015 and 2016)
- Instituto de Salud Carlos III (Sara Borrell fellowship CD17/00014)
This publication has 45 references indexed in Scilit:
- IBD prevalence in Lothian, Scotland, derived by capture–recapture methodologyGut, 2019
- Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseasesGut, 2018
- To respond or not to respond — a personal perspective of intestinal toleranceNature Reviews Immunology, 2018
- Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studiesThe Lancet, 2017
- Regulation of inflammation by microbiota interactions with the hostNature Immunology, 2017
- Human Intestinal Barrier Function in Health and DiseaseClinical and Translational Gastroenterology, 2016
- Compartmentalized and systemic control of tissue immunity by commensalsNature Immunology, 2013
- VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitisMolecular and Cellular Biochemistry, 2012
- Well‐controlled proinflammatory cytokine responses of Peyer’s patch cells to probiotic Lactobacillus caseiImmunology, 2010
- Anti-inflammatory activity of probiotic Bifidobacterium: Enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cellsWorld Journal of Gastroenterology, 2008